Lyell Immunopharma, Inc.
LYEL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $106 | $146 | $124 | $294 |
| Short-Term Investments | $265 | $401 | $517 | $321 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $9 | $8 | $11 | $11 |
| Total Curr. Assets | $380 | $555 | $651 | $626 |
| Property Plant & Equip (Net) | $73 | $142 | $166 | $167 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $32 | $49 | $115 | $331 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $6 | $5 | $5 | $4 |
| Total NC Assets | $111 | $195 | $286 | $501 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $491 | $750 | $938 | $1,127 |
| Liabilities | – | – | – | – |
| Payables | $5 | $5 | $4 | $3 |
| Short-Term Debt | $8 | $6 | $5 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $5 |
| Other Curr. Liab. | $40 | $23 | $29 | $37 |
| Total Curr. Liab. | $54 | $35 | $37 | $47 |
| LT Debt | $51 | $57 | $63 | $67 |
| Deferred Rev, NC | $0 | $0 | $0 | $80 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $3 | $4 | $4 | $5 |
| Total NC Liab. | $54 | $61 | $67 | $151 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $59 | $63 | $68 | $68 |
| Total Liabilities | $108 | $95 | $104 | $198 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,345 | -$1,002 | -$767 | -$584 |
| AOCI | $0 | -$0 | -$8 | -$2 |
| Other Equity | $1,728 | $1,657 | $1,608 | $1,516 |
| Total Equity | $383 | $655 | $833 | $930 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $491 | $750 | $938 | $1,127 |
| Net Debt | -$47 | -$82 | -$56 | -$226 |